Risk and protective factors for COVID-19 morbidity, severity, and mortality
J Zhang, X Dong, G Liu, Y Gao - Clinical reviews in allergy & immunology, 2023 - Springer
The outbreak of the coronavirus disease 2019 (COVID-19), caused by the novel severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global …
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become an evolving global …
COVID-19 vaccine development: milestones, lessons and prospects
M Li, H Wang, L Tian, Z Pang, Q Yang… - Signal transduction and …, 2022 - nature.com
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
(VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 …
Respiratory mucosal immunity against SARS-CoV-2 after mRNA vaccination
SARS-CoV-2 mRNA vaccination induces robust humoral and cellular immunity in the
circulation; however, it is currently unknown whether it elicits effective immune responses in …
circulation; however, it is currently unknown whether it elicits effective immune responses in …
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
The Omicron variant of SARS-CoV-2 is causing a rapid increase in infections across the
globe. This new variant of concern carries an unusually high number of mutations in key …
globe. This new variant of concern carries an unusually high number of mutations in key …
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Abstract Coronavirus Disease 2019 (COVID-19) has been the most severe public health
challenge in this century. Two years after its emergence, the rapid development and …
challenge in this century. Two years after its emergence, the rapid development and …
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Adjuvants are critical for improving the quality and magnitude of adaptive immune
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …
responses to vaccination. Lipid nanoparticle (LNP)-encapsulated nucleoside-modified …
Structural biology of SARS-CoV-2: open the door for novel therapies
W Yan, Y Zheng, X Zeng, B He, W Cheng - Signal Transduction and …, 2022 - nature.com
Abstract Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is the causative
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
agent of the pandemic disease COVID-19, which is so far without efficacious treatment. The …
Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in …
MD Tanriover, HL Doğanay, M Akova, HR Güner… - The Lancet, 2021 - thelancet.com
Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
to be well tolerated with a good safety profile in individuals aged 18 years and older in …
[HTML][HTML] Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone
progressive change, with variants conferring advantage rapidly becoming dominant …
progressive change, with variants conferring advantage rapidly becoming dominant …
[HTML][HTML] Neutralizing monoclonal antibodies for treatment of COVID-19
PC Taylor, AC Adams, MM Hufford… - Nature Reviews …, 2021 - nature.com
Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …